FDA Advisory Committees Would Get Patient Influence Under Hagan Bill
This article was originally published in The Tan Sheet
Executive Summary
Adjusting advisory committee conflict of interest rules becomes a high-priority issue in reauthorizing FDA’s drug user fee program. With several bills proposing to loosen the rules, Sen. Hagan’s draft FDA reform legislation could bring the most changes.